Latest Vectus Biosystems (ASX:VBS) News

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Vectus Biosystems has responded to an ASX price query following a dramatic spike in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

Vectus Biosystems has had its ASX trading suspension lifted following the disclosure of a significant transaction involving a compound from its drug library, signaling renewed investor interest.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

Vectus Biosystems has requested an immediate suspension of its ASX-listed shares pending a significant announcement about a transaction involving a compound in its drug library.

Vectus Biosystems has temporarily paused trading of its securities pending a forthcoming announcement, signaling potential material news for investors.

Vectus Biosystems has posted a 58% drop in revenue and a 24% reduction in operating loss for FY2025, but its net equity has swung into negative territory.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.